Jim Cramer Just Discussed These 13 Stocks

6. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders In Q3 2024: 80

Pfizer Inc. (NYSE:PFE) is one of the most well-known drug companies in the world. Its shares haven’t performed well at all in 2024 and are down 8% year-to-date. Pfizer Inc. (NYSE:PFE)’s heft has also led to it accumulating significant debt. As of 2023 end, the firm’s long-term debt was $61.5 billion. Debt impacts the bottom line, and for firms like Pfizer Inc. (NYSE:PFE) this means that dividends suffer. As a result, the firm has spent 2024 spinning off its business to raise cash and retire its debt. It has also faced pressure from activist investor Starboard over costly acquisitions that haven’t yielded profitable drugs. Cramer’s comments surrounded Pfizer Inc. (NYSE:PFE) CEO’s strategy for a turnaround and its 2025 earnings projection as he outlined:

“That’s very impressive.

“And I, you know what I think that Dr. Bourla, he’s done a lot of good worldwide. He’s done many things that I think are very positive for healthcare. I think that the issue has been, what about the numbers? Can he make the numbers?

“You hope that Seagen pays off. They bought Seagen off, the old Seattle Genetics, a lot of people felt they paid way too much. I have felt that if Dr. Bourla is correct about his roadmap of what’s going to come out of Seagen, we will all say that you know what, he got the last laugh.”